Literature DB >> 19817483

Robust-linear-model normalization to reduce technical variability in functional protein microarrays.

Andrea Sboner1, Alexander Karpikov, Gengxin Chen, Michael Smith, Dawn Mattoon, Mattoon Dawn, Lisa Freeman-Cook, Barry Schweitzer, Mark B Gerstein.   

Abstract

Protein microarrays are similar to DNA microarrays; both enabling the parallel interrogation of thousands of probes immobilized on a surface. Consequently, they have benefited from technologies previously developed for DNA microarrays. However, assumptions for the analysis of DNA microarrays do not always translate to protein arrays, especially in the case of normalization. Hence, we have developed an experimental and computational framework to assess normalization procedures for protein microarrays. Specifically, we profiled two sera with markedly different autoantibody compositions. To analyze intra- and interarray variability, we compared a set of control proteins across subarrays and the corresponding spots across multiple arrays, respectively. To estimate the degree to which the normalization could help reveal true biological separability, we tested the difference in the signal between the sera relative to the variability within replicates. Next, by mixing the sera in different proportions (titrations), we correlated the reactivity of proteins with serum concentration. Finally, we analyzed the effect of normalization procedures on the list of reactive proteins. We compared global and quantile normalization, techniques that have traditionally been employed for DNA microarrays, with a novel normalization approach based on a robust linear model (RLM) making explicit use of control proteins. We show that RLM normalization is able to reduce both intra- and interarray technical variability while maintaining biological differences. Moreover, in titration experiments, RLM normalization enhances the correlation of protein signals with serum concentration. Conversely, while quantile and global normalization can reduce interarray technical variability, neither is as effective as RLM normalization in maintaining biological differences. Most importantly, both introduce artifacts that distort the signals and affect the correct identification of reactive proteins, impairing their use for biomarker discovery. Hence, we show RLM normalization is better suited to protein arrays than approaches used for DNA microarrays.

Mesh:

Substances:

Year:  2009        PMID: 19817483     DOI: 10.1021/pr900412k

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  35 in total

Review 1.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

2.  Endothelial cell antibodies associated with novel targets and increased rejection.

Authors:  Annette M Jackson; Tara K Sigdel; Marianne Delville; Szu-Chuan Hsieh; Hong Dai; Serena Bagnasco; Robert A Montgomery; Minnie M Sarwal
Journal:  J Am Soc Nephrol       Date:  2014-11-07       Impact factor: 10.121

3.  Gain-Scanning for Protein Microarray Assays.

Authors:  Feng Feng; Sila Toksoz Ataca; Mingxuan Ran; Yumei Wang; Michael Breen; Thomas B Kepler
Journal:  J Proteome Res       Date:  2020-01-23       Impact factor: 4.466

4.  Profiling of autoantibodies in IgA nephropathy, an integrative antibiomics approach.

Authors:  Tara K Sigdel; Sang Hoon Woo; Hong Dai; Purvesh Khatri; Li Li; Bryan Myers; Minnie M Sarwal; Richard A Lafayette
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

5.  Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria.

Authors:  Jason A Bailey; Jozelyn Pablo; Amadou Niangaly; Mark A Travassos; Amed Ouattara; Drissa Coulibaly; Matthew B Laurens; Shannon L Takala-Harrison; Kirsten E Lyke; Jeff Skinner; Andrea A Berry; Algis Jasinskas; Rie Nakajima-Sasaki; Bourema Kouriba; Mahamadou A Thera; Philip L Felgner; Ogobara K Doumbo; Christopher V Plowe
Journal:  Am J Trop Med Hyg       Date:  2014-10-06       Impact factor: 2.345

6.  Antibody profiling of bipolar disorder using Escherichia coli proteome microarrays.

Authors:  Po-Chung Chen; Guan-Da Syu; Kuo-Hsuan Chung; Yu-Hsuan Ho; Feng-Hsiang Chung; Pao-Huan Chen; Jyun-Mu Lin; Yi-Wen Chen; Shang-Ying Tsai; Chien-Sheng Chen
Journal:  Mol Cell Proteomics       Date:  2014-12-24       Impact factor: 5.911

7.  Mapping novel immunogenic epitopes in IgA nephropathy.

Authors:  Sang Hoon Woo; Tara K Sigdel; Van T Dinh; Minh-Thien Vu; Minnie M Sarwal; Richard A Lafayette
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 8.237

8.  Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities.

Authors:  Danica A Helb; Kevin K A Tetteh; Philip L Felgner; Jeff Skinner; Alan Hubbard; Emmanuel Arinaitwe; Harriet Mayanja-Kizza; Isaac Ssewanyana; Moses R Kamya; James G Beeson; Jordan Tappero; David L Smith; Peter D Crompton; Philip J Rosenthal; Grant Dorsey; Christopher J Drakeley; Bryan Greenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

9.  Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.

Authors:  Li Zhang; Harini Kandadi; Hai Yang; Jason Cham; Tao He; David Y Oh; Nadeem A Sheikh; Lawrence Fong
Journal:  Cancer Immunol Res       Date:  2020-09-23       Impact factor: 11.151

Review 10.  A systems biology approach for diagnostic and vaccine antigen discovery in tropical infectious diseases.

Authors:  Li Liang; Philip L Felgner
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.